2024 Scientific Sessions

Lunch Program: The Holy Grail:  How Can We Resolve Microvascular Dysfunction in STEMI?

Despite advances in epicardial focused primary PCI, STEMI outcomes have stagnated over the past 20 years, with 1 in 5 patients developing heart failure at 1 year.  Recent research is clear that microvascular obstruction plays a significant role in determining eventual patient outcomes. Hear global thought leaders discuss the rationale and science behind diagnosing and treating microvascular disease in STEMI.   Learn how SuperSaturated Oxygen Therapy can not only reduce infarct size but also address the underlying microvascular dysfunction.

This activity is not certified for accredited continuing education.

Introduction
Steven J. Yakubov, M.D., MSCAI, OhioHealth Heart & Vascular Physicians, Columbus, OH
Importance of the Microvasculature on STEMI Outcomes
Timothy D. Henry, M.D., MSCAI, The Christ Hospital Health Network, Covington, KY
Imaging Techniques to Evaluate MVO
Joao L. Cavalcante, M.D., Minneapolis Heart Institute® - Abbott Northwestern Hospital, Minneapolis, MN
Techniques to Assess Microvascular Dysfunction
Megha Prasad, M.D., NewYork-Presbyterian Columbia University Irving Medical Center, new york city, NY
Future Directions in the Treatment of STEMI
Brian C Case, MD, FSCAI, MedStar Heart & Vascular Institute , Washington, DC
SSO2 Impact on Microvascular Dysfunction
Sandeep Nathan, M.D., FSCAI, The University of Chicago, Chicago, IL